Skip to main content
Open medical journals, reading glasses and a stethoscope on a desk
Research

Publications

Selected peer-reviewed research by the physicians who founded OIC Inspired and run Orlando Immunology Center, the clinical research site in our building, from 2014 to today. Each entry links to the paper on PubMed and to its DOI. Authors from our team are shown in bold.

This page is a selection. The complete list of more than 200 papers by the same physicians is on oicorlando.com/publications.

In several large multicenter trials our physicians served as site investigators and are listed in the study group rather than on the author byline. Those entries are marked "site investigator".

2026

  1. Safety, pharmacokinetics, and antiviral activity of a combination of TMB-365 and TMB-380 in people living with HIV suppressed with antiretroviral therapy in the USA: a phase 1b/2a, open-label, dose-escalation study The Lancet HIV · 2026 Markowitz M, Lalezari JP, DeJesus E, Sension MG, Richmond G, Crofoot G, et al. PubMed

2023

  1. Risk of COVID-19 after natural infection or vaccination EBioMedicine · 2023 Site investigator Rick AM, Laurens MB, Huang Y, Yu C, Martin TCS, Rodriguez CA, et al. Site investigators: Charlotte-Paige Rolle, MD, Stephanie Skipper, APRN PubMed
  2. Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials EClinicalMedicine · 2023 Sax PE, Arribas JR, Orkin C, Lazzarin A, Pozniak A, DeJesus E, et al. PubMed
  3. Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19 Annals of internal medicine · 2023 Site investigator Evering TH, Chew KW, Giganti MJ, Moser C, Pinilla M, Wohl DA, et al. Site investigator: Charlotte-Paige Rolle, MD PubMed
  4. Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks Open forum infectious diseases · 2023 Rolle CP, Berhe M, Singh T, Ortiz R, Wurapa A, Ramgopal M, et al. PubMed
  5. Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials JAMA network open · 2023 Site investigator Theodore DA, Branche AR, Zhang L, Graciaa DS, Choudhary M, Hatlen TJ, et al. Site investigators: Charlotte-Paige Rolle, MD, Stephanie Skipper, APRN PubMed
  6. Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting Antiviral therapy · 2023 Rolle CP, Castano J, Nguyen V, Patel K, Hinestrosa F, DeJesus E PubMed
  7. Racial/ethnic disparities in HIV care outcomes among insured patients at a large urban sexual health clinic Journal of investigative medicine · 2023 Mathai R, Hinestrosa F, DeJesus E, Rolle CP PubMed
  8. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection The New England Journal of Medicine · 2023 Site investigator Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, et al. Site investigator: Edwin DeJesus, MD, FACP, FIDSA PubMed

2022

  1. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection The New England Journal of Medicine · 2022 Segal-Maurer S, DeJesus E, Stellbrink HJ, Castagna A, Richmond GJ, Sinclair GI, et al. PubMed
  2. From declining PrEP to PrEP initiation as "first nature" - what changes PrEP initiation decisions among young, Black MSM AIDS care · 2022 Huang W, Lockard A, Kelley CF, Serota DP, Rolle CM, Sullivan PS, et al. PubMed
  3. Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1 Antimicrobial agents and chemotherapy · 2022 Gartland M, Cahn P, DeJesus E, Diaz RS, Grossberg R, Kozal M, et al. PubMed
  4. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial Nature medicine · 2022 Julg B, Stephenson KE, Wagh K, Tan SC, Zash R, Walsh S, Rolle CP, DeJesus E, et al. PubMed
  5. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial JAMA · 2022 Site investigator O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, et al. Site investigators: Charlotte-Paige Rolle, MD, Federico Hinestrosa, MD, FACP, FIDSA, Stephanie Skipper, APRN, Terry Wilder, APRN PubMed
  6. Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study Open forum infectious diseases · 2022 Sutton KC, De Vente J, Leblanc R, Dejesus E, Smith G, Mills A, et al. PubMed
  7. Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated Frontiers in immunology · 2022 Maaske J, Sproule S, Falsey AR, Sobieszczyk ME, Luetkemeyer AF, Paulsen GC, Rolle CP, et al. PubMed

2021

  1. Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV Medicine · 2021 Rolle CP, Nguyen V, Patel K, Cruz D, DeJesus E, Hinestrosa F PubMed
  2. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 The New England Journal of Medicine · 2021 Site investigator O'Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan KC, Sarkar N, et al. Site investigators: Federico Hinestrosa, MD, FACP, FIDSA, Stephanie Skipper, APRN, Terry Wilder, APRN PubMed
  3. Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV AIDS (London, England) · 2021 Rolle CP, Berhe M, Singh T, Ortiz R, Wurapa A, Ramgopal M, et al. PubMed
  4. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial Nature medicine · 2021 Stephenson KE, Julg B, Tan CS, Zash R, Walsh SR, Rolle CP, DeJesus E, et al. PubMed
  5. Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV AIDS research and therapy · 2021 Rolle CP, Nguyen V, Hinestrosa F, DeJesus E PubMed
  6. The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy Science translational medicine · 2021 SenGupta D, Brinson C, DeJesus E, Mills A, Shalit P, Guo S, et al. PubMed
  7. Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1 Clinical infectious diseases · 2021 Riddler SA, Para M, Benson CA, Mills A, Ramgopal M, DeJesus E, et al. PubMed
  8. Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial The Lancet HIV · 2021 Molina JM, Yazdanpanah Y, Afani Saud A, Bettacchi C, Chahin Anania C, DeJesus E, et al. PubMed
  9. Determinants of pre-exposure prophylaxis (PrEP) persistence in a high-risk population in Central Florida Journal of investigative medicine · 2021 Keyes J, Crouse EC, DeJesus E, Rolle CP PubMed
  10. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine The New England Journal of Medicine · 2021 Site investigator Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, DeJesus E, et al. Site investigators: Charlotte-Paige Rolle, MD, Stephanie Skipper, APRN PubMed
  11. A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study Hepatology (Baltimore, Md.) · 2021 Sulkowski MS, Moon JS, Sherman KE, Morelli G, Darling JM, Muir AJ, Hinestrosa F, et al. PubMed

2020

  1. Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance-associated mutations through 48 weeks of treatment International journal of STD & AIDS · 2020 Rolle CP, Marquez O, Nguyen V, Hinestrosa F, DeJesus E PubMed
  2. Clinical outcomes of HIV-1 infected patients switched from complex multi-tablet regimens to tenofovir alafenamide based single-tablet regimens plus a boosted protease inhibitor in a real-world setting Journal of virus eradication · 2020 Rolle CP, Nguyen V, Hinestrosa F, DeJesus E PubMed
  3. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection The New England Journal of Medicine · 2020 Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina JM, DeJesus E, et al. PubMed
  4. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials The Lancet HIV · 2020 Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, et al. PubMed
  5. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial The Lancet · 2020 Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, DeJesus E, et al. PubMed
  6. A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection Clinical infectious diseases · 2020 DeJesus E, Harward S, Jewell RC, Johnson M, Dumont E, Wilches V, et al. PubMed
  7. HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens PloS one · 2020 Huhn GD, Ramgopal M, Jain MK, Hinestrosa F, Asmuth DM, Slim J, et al. PubMed

2019

  1. PrEP Implementation and Persistence in a County Health Department Setting in Atlanta, GA AIDS and behavior · 2019 Rolle CP, Onwubiko U, Jo J, Sheth AN, Kelley CF, Holland DP PubMed
  2. Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial Journal of acquired immune deficiency syndromes (1999) · 2019 Kityo C, Hagins D, Koenig E, Avihingsanon A, Chetchotisakd P, Supparatpinyo K, DeJesus E, et al. PubMed
  3. Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy Gastroenterology · 2019 Lok AS, Sulkowski MS, Kort JJ, Willner I, Reddy KR, Shiffman ML, Hinestrosa F, et al. PubMed

2017

  1. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen Hepatology (Baltimore, Md.) · 2017 Gane EJ, Shiffman ML, Etzkorn K, Morelli G, Stedman CAM, Davis MN, Hinestrosa F, et al. PubMed
  2. Challenges in Translating PrEP Interest Into Uptake in an Observational Study of Young Black MSM Journal of acquired immune deficiency syndromes (1999) · 2017 Rolle CP, Rosenberg ES, Siegler AJ, Sanchez TH, Luisi N, Weiss K, et al. PubMed
  3. Willingness to use pre-exposure prophylaxis among Black and White men who have sex with men in Atlanta, Georgia International journal of STD & AIDS · 2017 Rolle CP, Rosenberg ES, Luisi N, Grey J, Sanchez T, Del Rio C, et al. PubMed

2016

  1. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial Gastroenterology · 2016 Lawitz E, Reau N, Hinestrosa F, Rabinovitz M, Schiff E, Sheikh A, et al. PubMed
  2. Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients Liver international · 2016 Everson GT, Sims KD, Thuluvath PJ, Lawitz E, Hassanein T, Rodriguez-Torres M, Hinestrosa F, et al. PubMed
  3. Use of a Prospective Sex Diary to Study Anal Lubricant and Enema Use Among High Risk Men Who Have Sex With Men-Implications for Human Immunodeficiency Virus Prevention Sexually transmitted diseases · 2016 Rolle CP, Bolton MD, Kelley CF PubMed

2015

  1. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial Annals of internal medicine · 2015 Everson GT, Towner WJ, Davis MN, Wyles DL, Nahass RG, Thuluvath PJ, Hinestrosa F, et al. PubMed
  2. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1 The New England Journal of Medicine · 2015 Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, Hinestrosa F, et al. PubMed

2014

  1. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection The New England Journal of Medicine · 2014 Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Hinestrosa F, et al. PubMed

Full list of publications: oicorlando.com/publications. Want to join a study? Orlando Immunology Center lists enrolling studies at oicorlando.com, (407) 374-0220.